all the information, none of the junk | biotech • healthcare • life sciences

Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today

(Page 2 of 2)

it’s basically consistent with the 12 percent decline in that same time frame for the Amex Biotechnology Index, a 20-member index of large biotech peers of Biogen.

Just as a last-minute reminder, since this might not be a black-and-white 4-0 victory for either side, here’s a list of the individual nominees from each slate that you can refer to when the tally is announced. Xconomy’s Roxanne Palmer will serve as our eyes and ears at the meeting this morning when the votes are announced, so watch this space for updates this morning.

Carl Icahn’s nominees are:

—Alex Denner, 39, a portfolio manager for Icahn in New York, and a veteran of several biotech proxy contests. Denner served on the board of New York-based ImClone Systems as it changed from an industry laughingstock into an emerging cancer drug developer that was ultimately acquired by Eli Lilly for more than $6 billion. This week, Denner was elected to the board of San Diego-based Amylin Pharmaceuticals.

—Richard Mulligan, 54, is a professor of genetics at Harvard Medical School in Boston, and director of the Harvard Gene Therapy Initiative.

—Thomas Deuel, 73, is a professor of molecular and experimental medicine and cell biology at The Scripps Research Institute in San Diego.

—David Sidransky, 48, is the director of the head and neck cancer research division at Johns Hopkins University School of Medicine in Baltimore, MD.

Biogen’s nominees are:

—Lawrence Best, 59, the chairman and founder of OXO Capital, a privately-held investment company. He was formerly the chief financial officer of Natick, MA-based Boston Scientific. He’s been on the Biogen board since 2003.

—Alan Glassberg, 72, a venture partner and member of the scientific advisory board of San Francisco-based Bay City Capital, a life sciences investment firm. He’s been on the Biogen board since 1997.

—Robert Pangia, 57, a partner at Montvale, NJ-based Ivy Capital Partners, a private equity fund specializing in health care investments. He’s also been on the Biogen board since 1997.

—William Young, 64, is chairman and CEO of South San Francisco-based Monogram Biosciences, a maker of molecular diagnostic products. He, too, has been on Biogen’s board since 1997.

Single PageCurrently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.

Comments are closed.